You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The planned joint venture with Beijing Zishan Health Consultancy is aimed at bringing Genetic Technologies' genomic tests to the Chinese market.
The JV is expected to grow the outreach business by combining state-of-the-art lab facilities with Sonic's connectivity and analytics capabilities.
The JV, called ProMedica Pathology Laboratories, will combine the inpatient and outreach testing capabilities as well as esoteric testing capabilities of the partners.
A new company will be established to develop a service platform using blockchain technology for medical services and personalized health management.
Factors like the country's interest in multiplexed dx panels and wellness monitoring have its clinical mass spec space "poised for huge growth," said a Sciex official.
The venture with the Chinese diagnostics firm will focus on developing and commercializing tests and reagents for Scienx's 4500MD triple quad mass spec system.
The companies formed the joint venture in 2008 to commercialize BioMérieux's IVD products and medical instruments in Japan.
The new company will develop microbiome diagnostics for multiple indications including inflammatory bowel disease and liver disorders.
Fulgent reached an agreement with two Chinese firms to establish a joint venture to offer genetic testing services in China.
The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.